Patents by Inventor Hedi Haddada

Hedi Haddada has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Defective recombinant adenoviruses expressing cytokines for antitumor treatment
    Publication number: 20050048031
    Abstract: Recombinant nucleic acid for use in the production of a defective adenovirus containing an inserted sequence coding for a cytokine under the control of a promoter in the genomic sequence of the recombinant adenovirus. Said recombinant adenovirus is useful in the preparation of anti-tumoral drugs capable of being directly injected into the tumor of the host.
    Type: Application
    Filed: September 13, 2004
    Publication date: March 3, 2005
    Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT GUSTAVE ROUSSY
    Inventors: Hedi Haddada, Thierry Ragot, Michel Perricaudet
  • Medicinal combination useful for in vivo exogenic transfection and expression
    Publication number: 20040265276
    Abstract: A medical combination of at least one immunosuppressive agent and at least one recombinant adenovirus with a genome that includes a first recombinant DNA containing a therapeutic gene, and a second recombinant DNA containing an immunoprotective gene, for consecutive, intermittent and/or simultaneous use in in vivo and/or ex vivo exogenic transfections.
    Type: Application
    Filed: April 14, 2004
    Publication date: December 30, 2004
    Inventors: Michel Perricaudet, Lucienne Chatenoud, Hedi Haddada, Jean-Francois Bach, Michelle Webb
  • RECOMBINANT ADENOVIRAL VECTORS FOR HUMAN TUMOUR GENE THERAPY
    Publication number: 20030082150
    Abstract: A method for treating human tumours by gene therapy is disclosed. In particular, defective recombinant viruses with a sequence coding for a human tumour-specific antigen, and the use thereof for treating or preventing human tumours, as well as producing specific cytotoxic T-cells (CTLs) in vitro or ex vivo, are disclosed. Pharmaceutical compositions comprising said viruses, particularly in injectable form, are also disclosed.
    Type: Application
    Filed: October 5, 1998
    Publication date: May 1, 2003
    Inventors: THIERRY BOON-FALLEUR, MARIE-THERESE DUFFOUR, HEDI HADDADA, CHRISTOPHE LURQUIN, MICHEL PERRICAUDET, CATHERINE UYTTENHOVE-GHESQUIERE, GUY WARNIER
  • MEDICINAL COMBINATION USEFUL FOR IN VIVO EXOGENIC TRANSFECTION AND EXPRESSION
    Publication number: 20030004091
    Abstract: A medical combination of at least one immunosuppressive agent and at least one recombinant adenovirus with a genome that includes a first recombinant DNA containing a therapeutic gene, and a second recombinant DNA containing an immunoprotective gene, for consecutive, intermittent and/or simultaneous use in in vivo and/or ex vivo exogenic transfections.
    Type: Application
    Filed: May 22, 1998
    Publication date: January 2, 2003
    Inventors: MICHEL PERRICAUDET, MARTIN LEE, LUCIENNE CHATENOUD, HEDI HADDADA, JEAN-FRANCOIS BACH, MICHELLE WEBB
  • DEFECTIVE RECOMBINANT ADENOVIRUSES EXPRESSING CYTOKINES FOR ANTITUMOR TREATMENT
    Publication number: 20020031499
    Abstract: Recombinant nucleic acid for use in the production of a defective adenovirus containing an inserted sequence coding for a cytokine under the control of a promotor in the genomic sequence of the recombinant adenovirus. Said recombinant adenovirus is useful in the preparation of anti-tumoral drugs capable of being directly injected into the tumour of the host.
    Type: Application
    Filed: December 3, 1998
    Publication date: March 14, 2002
    Inventors: HEDI HADDADA, THIERRY RAGOT, MICHEL PERRICAUDET
  • Adenoviral vectors of canine origin
    Patent number: 6294377
    Abstract: The present invention resides in use of a recombinant adenovirus of animal origin containing a heterologous DNA sequence for the preparation of a pharmaceutical composition intended for the therapeutic and/or surgical treatment of the human body.
    Type: Grant
    Filed: November 17, 1995
    Date of Patent: September 25, 2001
    Assignee: Rhone-Poulenc Rorer SA
    Inventors: Hedi Haddada, Bernard Klonjkowski, Michel Perricaudet, Emmanuelle Vigne
  • Recombinant cells from the monocyte-macrophage cell line for gene therapy
    Patent number: 6210963
    Abstract: Cell compositions containing mononuclear phagocyte systems cells, and their use in cell therapy, e.g. adoptive immunotherapy, are disclosed.
    Type: Grant
    Filed: April 24, 1996
    Date of Patent: April 3, 2001
    Assignees: Institut National de la Sante et de la Recherche Medicale, Rhone-Poulenc Rorer S.A.
    Inventors: Hedi Haddada, Manuel Lopez, Michel Perricaudet
  • Adenoviral vectors of canine origin
    Patent number: 5891715
    Abstract: The present invention resides in use of a recombinant adenovirus of animal origin containing a heterologous DNA sequence for the preparation of a pharmaceutical composition intended for the therapeutic and/or surgical treatment of the human body.
    Type: Grant
    Filed: November 17, 1995
    Date of Patent: April 6, 1999
    Assignee: Rhone-Poulenc Rorer SA
    Inventors: Hedi Haddada, Bernard Klonjkowski, Michel Perricaudet, Emmanuelle Vigne